Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Sweden

European Research Council grant · Finished

hmqPro Highly multiplexed, quantitative protein biomarker profiling (hmqPro)

Coordinator
Karolinska Institutet, Sweden
Runs
1 July 2022 to 31 December 2023
Status
Finished
EU funding
€150k
Total cost
—
Partners
2 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101069454

What the project is doing

In the project's own words, from its summary on CORDIS.

The project will develop a multipurpose, highly multiplexed, quantitative protein profiling (hmqPro) platform that can be adapted to a wide range of applications, particularly biomarker discovery. Biomarkers are a 43 Billion USD market spanning applications in diagnostics, drug discovery & development, personalized medicine, disease risk assessment. The method comprises an antibody-based profiling of a large number of proteins or protein posttranslational modifications against a large number of samples irrespective of source.

Unlike competitor methods, hmqPro does not require platform-specific assay or detection equipment. Dual multiplexing implemented in a variant method, hmqPro-2D, will make the platform competitive against existing protein profiling methods in per-assay cost, flexibility and scalability. The hmqPro platform uniquely complements the technology portfolio of Epigenica AB and we will chart out two commercialization routes: first, hmqPro will be integrated into a service laboratory offering high-throughput sample-to-result epigenome and protein profiling services to academia, pharma and biotech industries.

Second, we will package the method in a kit format distributed to R&D and clinical end users. In summary, the proposed project will deliver a new quantitative protein profiling platform that will have the capacity to impact the biomarker discovery market by combining unique flexibility with high-throughput.

Topics

Who is involved

OrganisationCityCountryRole
Karolinska InstitutetStockholmSwedenCoordinator
Epigenica ABStockholmSwedenParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI